Defilade Capital Management
Latest statistics and disclosures from Defilade Capital Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002088557
Tip: Access up to 7 years of quarterly data
Positions held by Defilade Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Defilade Capital Management
Defilade Capital Management holds 31 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Zimmer Holdings (ZBH) | 7.4 | $52M | 579k | 90.42 |
|
|
| Henry Schein (HSIC) | 6.5 | $46M | 624k | 73.70 |
|
|
| Becton, Dickinson and (BDX) | 6.2 | $44M | 279k | 157.23 |
|
|
| Pfizer (PFE) | 5.8 | $41M | 1.5M | 28.08 |
|
|
| Dex (DXCM) | 4.8 | $34M | 539k | 62.80 |
|
|
| ICU Medical, Incorporated (ICUI) | 4.6 | $33M | 254k | 129.15 |
|
|
| Insmed Com Par $.01 (INSM) | 4.5 | $32M | 195k | 163.52 |
|
|
| Intuitive Surgical Com New (ISRG) | 4.4 | $31M | 68k | 460.99 |
|
|
| Revolution Medicines (RVMD) | 4.3 | $31M | 316k | 97.25 |
|
|
| Globus Med Cl A (GMED) | 4.3 | $31M | 354k | 86.16 |
|
|
| Neurocrine Biosciences (NBIX) | 3.9 | $28M | 210k | 131.74 |
|
|
| Denali Therapeutics (DNLI) | 3.7 | $26M | 1.4M | 19.20 |
|
|
| Ptc Therapeutics I (PTCT) | 3.6 | $26M | 376k | 68.13 |
|
|
| Olema Pharmaceuticals (OLMA) | 3.1 | $22M | 1.5M | 14.91 |
|
|
| Elanco Animal Health (ELAN) | 3.1 | $22M | 931k | 23.93 |
|
|
| Pacs Group Com Shs (PACS) | 2.7 | $19M | 604k | 32.12 |
|
|
| Eli Lilly & Co. (LLY) | 2.7 | $19M | 21k | 919.77 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.7 | $19M | 249k | 75.85 |
|
|
| Integer Hldgs (ITGR) | 2.6 | $19M | 213k | 88.00 |
|
|
| Biogen Idec (BIIB) | 2.5 | $18M | 96k | 183.33 |
|
|
| Evommune Com Shs (EVMN) | 2.2 | $16M | 679k | 22.99 |
|
|
| Tandem Diabetes Care Com New (TNDM) | 2.1 | $15M | 762k | 19.17 |
|
|
| Cogent Biosciences (COGT) | 1.9 | $14M | 353k | 38.49 |
|
|
| Nuvalent Inc-a (NUVL) | 1.9 | $13M | 130k | 102.45 |
|
|
| Ocular Therapeutix (OCUL) | 1.8 | $13M | 1.5M | 8.47 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.7 | $12M | 52k | 228.73 |
|
|
| Align Technology (ALGN) | 1.6 | $12M | 67k | 171.43 |
|
|
| Eledon Pharmaceuticals (ELDN) | 1.5 | $11M | 3.6M | 3.08 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.5 | $11M | 843k | 12.67 |
|
|
| Biohaven (BHVN) | 0.4 | $2.7M | 316k | 8.46 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.4 | $2.5M | 7.6M | 0.33 |
|
Past Filings by Defilade Capital Management
SEC 13F filings are viewable for Defilade Capital Management going back to 2026
- Defilade Capital Management 2026 Q1 restated filed June 12, 2026